Corcept Therapeutics Inc.

CORT Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of CORT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CORT Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
CORT Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CORT Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in CORT holdings by institutional investors

Insider Trading

Quarterly net insider trading by CORT's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

CORT Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

CORT Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
CORT Income Statement
CORT Balance Sheet
CORT Cash Flow
U.S. Patents

New CORT patent grants

  • Patent Title: Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist Oct. 14, 2025
  • Patent Title: Treatments for amyotrophic lateral sclerosis using dazucorilant Oct. 07, 2025
  • Patent Title: Formulations of dazucorilant, a glucocorticoid receptor modulator Jul. 29, 2025
  • Patent Title: Glucocorticoid receptor modulators to treat pancreatic cancer Jul. 29, 2025
  • Patent Title: Methods for shrinking pituitary tumors Jun. 24, 2025
  • Patent Title: Methods for imaging and treatment of somatostatin-receptor positive tumors May. 06, 2025
  • Patent Title: Glucocorticoid receptor modulators to treat cervical cancer Apr. 29, 2025
  • Patent Title: Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators Apr. 01, 2025
  • Patent Title: Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Feb. 18, 2025
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Feb. 18, 2025
  • Patent Title: Quaternary indazole glucocorticoid receptor antagonists Dec. 31, 2024
  • Patent Title: Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors Dec. 24, 2024
  • Patent Title: Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Nov. 26, 2024
  • Patent Title: Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 19, 2024
  • Patent Title: Octahydro fused azadecalin glucocorticoid receptor modulators Nov. 12, 2024
  • Patent Title: Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 12, 2024
  • Patent Title: Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers Oct. 08, 2024
  • Patent Title: Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators Oct. 01, 2024
  • Patent Title: Piperazine indazole glucocorticoid receptor antagonists Sep. 24, 2024
  • Patent Title: Bicyclic indazole glucocorticoid receptor antagonists Sep. 24, 2024
  • Patent Title: Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors Sep. 24, 2024
  • Patent Title: Pyrimidine cyclohexenyl glucocorticoid receptor modulators Jun. 25, 2024
  • Patent Title: Systems and methods of treatment using intervention and tasking determination Jun. 12, 2018
  • Patent Title: Systems and methods of managing treatment of a chronic condition by symptom tracking May. 22, 2018
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators May. 01, 2018
  • Patent Title: Optimizing mifepristone levels for cushing's patients Apr. 17, 2018
  • Patent Title: Glucocorticoid receptor modulators to treat pancreatic cancer Apr. 17, 2018
  • Patent Title: Method for differentially diagnosing acth-dependent cushing's syndrome Nov. 28, 2017
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Jul. 18, 2017
  • Patent Title: Pyrimidine cyclohexyl glucocorticoid receptor modulators Apr. 26, 2016
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Mar. 01, 2016
  • Patent Title: Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists Dec. 30, 2014
  • Patent Title: Pyrimidine cyclohexyl glucocorticoid receptor modulators Dec. 09, 2014
  • Patent Title: Solid forms and process for preparing Nov. 18, 2014
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Oct. 14, 2014
  • Patent Title: Combination steroid and glucocorticoid receptor antagonist therapy Sep. 09, 2014
  • Patent Title: Antiglucocorticoid therapy for the prevention of neurological damage in premature infants Jun. 03, 2014
  • Patent Title: Pyrimidine cyclohexyl glucocorticoid receptor modulators Apr. 01, 2014
  • Patent Title: Pyridyl-amine fused azadecalin modulators Dec. 03, 2013
  • Patent Title: Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists Dec. 03, 2013
  • Patent Title: Fused ring azadecalin glucocorticoid receptor modulators Oct. 15, 2013
  • Patent Title: Methods for treating psychosis associated with interferson-α therapy Jul. 02, 2013
  • Patent Title: Solid forms and process for preparing Jun. 11, 2013
  • Patent Title: Methods for treating migraine May. 28, 2013
  • Patent Title: Azadecalin glucocorticoid receptor modulators Dec. 04, 2012
  • Patent Title: Modified pyrimidine glucocorticoid receptor modulators May. 08, 2012
  • Patent Title: Antiglucocorticoids for the treatment of catatonia Jan. 17, 2012
  • Patent Title: Fused ring azadecalin glucocorticoid receptor modulators Apr. 19, 2011
  • Patent Title: Methods for treating delirium using glucocorticoid receptor-specific antagonists Feb. 08, 2011
  • Patent Title: Azadecalin glucocorticoid receptor modulators Mar. 16, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to CORT from public contracts

CORT News

Recent insights relating to CORT

CNBC Recommendations

Recent picks made for CORT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CORT

CORT Analyst Ratings

CORT Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
CORT Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $CORT stock a Buy, Sell, or Hold?

  • What is the price target for $CORT stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

CORT Top Shareholders
Shareholder
Shares Held
CORT Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $CORT stock?

  • Who owns the most shares of $CORT stock?

  • What funds own $CORT stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CORT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CORT Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About CORT

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

  • Address Redwood City, CA
  • Market Cap 8.1 billion
  • Employees 500
  • Industrial Classification Pharmaceutical Preparations
Back To Top